2024 ASCO Annual Meeting features MediciNova's clinical trial abstract of MN-166 (ibudilast) for glioblastoma in combination with temozolomide.

MediciNova, a NASDAQ-listed and Tokyo-listed biopharmaceutical company, is presenting a clinical trial abstract of MN-166 (ibudilast) for glioblastoma at the 2024 ASCO Annual Meeting. MN-166 is a small molecule compound that targets phosphodiesterase type-4 (PDE4) and inflammatory cytokines. The trial will evaluate its combination with temozolomide in newly diagnosed and recurrent glioblastoma patients.

April 02, 2024
4 Articles